Herbert Loong, Clinical Associate Professor at The Chinese University of Hong Kong, and Steering Committee Member at Lung Cancer Policy Network, shared a post on X:
“Kicking off activities at ESMO Asia 25 with a short talk on AI driven Biomarkers and what are the potentials and implications of these in drug development and oncology clinical care.
A shoutout to the just released EBAI guidance document.”
Title: ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI)
Authors: M. Aldea, M. Salto-Tellez, A. Marra, R. Umeton, A. Stenzinger, M. Koopman, A. Prelaj, K. L. Kehl, S. Gilbert, M-E. Leßmann, J. Lipkova, L. Provenzano, F. Meric-Bernstam, S. Halabi, J. Wu, A. Pellat, K. P. M. Suijkerbuijk, B. Besse, B. Ryll, C. Marchió, M. Crispin-Ortuzar, R. Fehrmann, J. Vibert, D. Ferber, C. Pauli, A. Valachis, Federica Corso, T. J. Brinker, J. Mateo, N. Harbeck, E. C. Winkler, F. Lopez-Rios, R. Perez-Lopez, G. Pentheroudakis, S. Delaloge, C. Benedikt Westphalen, J. N. Kather
Read the Full Article on ESMO Open
More posts about ESMO Asia 2025
